182 related articles for article (PubMed ID: 36266066)
1. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
3. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
4. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, Melphalan, Dexamethasone: A New Standard of Care for AL Amyloidosis?
Pratt G
J Clin Oncol; 2020 Oct; 38(28):3243-3244. PubMed ID: 32749940
[No Abstract] [Full Text] [Related]
7. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
8. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
10. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
11. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
[TBL] [Abstract][Full Text] [Related]
17. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
[TBL] [Abstract][Full Text] [Related]
18. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V; Palladini G; Minnema MC; Jaccard A; Lee HC; Gibbs S; Mollee P; Venner C; Lu J; Schönland S; Gatt M; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Chauveau D; Gries KS; Fastenau J; Tran NP; Qin X; Vasey SY; Weiss BM; Vermeulen J; Ho KF; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD
Am J Hematol; 2022 Jun; 97(6):719-730. PubMed ID: 35293006
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
